Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Sera Prognostics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
26-1911522 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
2749 East Parleys Way
Suite 200
Salt Lake City, UT 84109
Telephone: (801) 990-0520
(Address, including zip code, and telephone number, including area code,
of registrant’s principal executive offices)
2021 Equity Incentive Plan
2021 Employee Stock Purchase Plan
(Full Title of the Plans)
Zhenya Lindgardt
President and Chief Executive Officer
Sera Prognostics, Inc.
2749 East Parleys Way
Suite 200
Salt Lake City, UT 84109
Telephone: (801) 990-0520
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
o |
Accelerated filer |
o |
Non-accelerated filer |
x |
Smaller reporting company |
x |
|
|
Emerging growth company |
x |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement registers 1,328,276 additional shares of Class A Common Stock, par value $0.0001 per share (“Common Stock”), of Sera Prognostics, Inc. (the “Registrant”) under the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and 332,069 additional shares of Common Stock under the Registrant’s 2021 Employee Stock Purchase Plan (the “ESPP”), representing an increase of 1,328,276 shares of Common Stock reserved for issuance under the 2021 Plan and 332,069 shares of Common Stock reserved for issuance under the ESPP, in each case effective January 1, 2025 by operation of the “evergreen” provision contained in the applicable plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File Nos. 333-258696, 333-263943, 333-270746, and 333-278104) (the “Prior Registration Statements”). The information contained in the Registrant’s Prior Registration Statements is hereby incorporated by reference pursuant to General Instruction E of Form S-8.
2
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits
Exhibit Number |
|
Exhibit Description |
|
Filed Herewith |
|
Incorporated by Reference herein from Form or Schedule |
|
Filing Date |
|
SEC File/Reg. Number |
|
|
|
|
|
|
|||||
|
Certificate of Amendment to Amended and Restated Certificate of Incorporation |
|
|
|
|
|
||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|||||
|
Fourth Amended and Restated Investors’ Rights Agreement, dated as of February 23, 2021 |
|
|
|
|
|
||||
|
|
|
|
|
|
|||||
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|||
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|||||
|
Form of Stock Option Agreement under the Registrant’s 2021 Equity Incentive Plan |
|
|
|
|
|
||||
|
Form of Restricted Stock Unit Agreement under the Registrant’s 2021 Equity Incentive Plan |
|
|
|
|
|
||||
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
__________________________________
+ Denotes management contract or compensatory plan or arrangement
3
Signatures
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized in Salt Lake City, Utah, on the 19th day of March, 2025.
SERA PROGNOSTICS, INC.
By: /s/ Zhenya Lindgardt
Zhenya Lindgardt
President and Chief Executive Officer
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints each of Zhenya Lindgardt and Austin Aerts, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Zhenya Lindgardt |
|
President and Chief Executive Officer (Principal Executive Officer) |
|
March 19, 2025 |
Zhenya Lindgardt |
||||
|
|
|
|
|
/s/ Austin Aerts |
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
|
March 19, 2025 |
Austin Aerts |
||||
|
|
|
|
|
/s/ Kim Kamdar, Ph.D. |
|
Chair of the Board of Directors |
|
March 19, 2025 |
Kim Kamdar, Ph.D. |
||||
|
|
|
|
|
/s/ Jane F. Barlow, M.D. |
|
Director
|
|
March 19, 2025 |
Jane F. Barlow, M.D. |
||||
|
|
|
|
|
/s/ Gregory C. Critchfield, M.D., M.S. |
|
Director
|
|
March 19, 2025 |
Gregory C. Critchfield, M.D., M.S. |
||||
|
|
|
|
|
/s/ Sandra A.J. Lawrence |
|
Director
|
|
March 19, 2025 |
Sandra A.J. Lawrence |
||||
|
|
|
|
|
/s/ Mansoor Raza Mirza, M.D. |
|
Director
|
|
March 19, 2025 |
Mansoor Raza Mirza, M.D. |
||||
|
|
|
|
|
/s/ Joshua Phillips |
|
Director
|
|
March 19, 2025 |
Joshua Phillips |
|
|
||
|
|
|
|
|
/s/ Ryan Trimble |
|
Director
|
|
March 19, 2025 |
Ryan Trimble |
|
|
||
|
|
|
|
|
/s/ Marcus Wilson, Pharm.D. |
|
Director
|
|
March 19, 2025 |
Marcus Wilson, Pharm.D. |
|
|
4